ReviewThe Lancet. Infectious diseases2020
Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.
Review in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- [Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance].Dermatologie (Heidelberg, Germany) · 2026Review
- US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Trends in population structure, antimicrobial susceptibility and resistance determinants ofJAC-antimicrobial resistance · 2026Article
- Treatment 'cultures', sexually transmitted infections and the rise of antimicrobial resistance.Sociology of health & illness · 2025Article
- Antimicrobial treatment and resistance in sexually transmitted bacterial infections.Nature reviews. Microbiology · 2024Review
- Pharmacodynamics of zoliflodacin plus doxycycline combination therapy againstFrontiers in pharmacology · 2023Article
- The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.Current HIV/AIDS reports · 2022Review
- In Vitro Study of the Interaction of Gentamicin with Ceftriaxone and Azithromycin againstAntibiotics (Basel, Switzerland) · 2022Article
- Multiple pathogens and prostate cancer.Infectious agents and cancer · 2022Review
- A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance inAntimicrobial agents and chemotherapy · 2022Article
- Impact of Alternative Growth Supplements on Antimicrobial Susceptibility Testing ofInfection and drug resistance · 2022Article
- Evaluation ofInfection and drug resistance · 2022Article
- Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulatingFrontiers in pharmacology · 2022Article
- Potential of mucoadhesive chitosan glutamate microparticles as microbicide carriers - antiherpes activity and penetration behavior across the human vaginal epithelium.Drug delivery · 2021Article
- Review
- The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials.Pharmaceutics · 2021Review
- Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016.BMC infectious diseases · 2021Article
- Optimizations to keep gonorrhoea treatable and reduce antimicrobial resistance selection.Nature reviews. Urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 4 countries.
Funding
Abstract
Progressive antimicrobial resistance in Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis has created a pressing need for treatment optimisations for sexually transmitted infections (STIs). In this Review, we aim to highlight urgent needs in global STI management, including: (1) improved surveillance to monitor antimicrobial resistance and clinical outcomes; (2) systematic pharmacokinetic and pharmacodynamic evaluations to ensure resistance suppression and bacterial eradication at all sites of infection; (3) development of novel, affordable antimicrobials; and (4) advancements in new molecular and point-of-care tests to detect antimicrobial resistance determinants. Antimicrobial resistance among STIs is a global public health crisis. Continuous efforts to develop novel antimicrobials will be essential, in addition to other public health interventions to reduce the global STI burden. Apart from prevention through safer sexual practices, the development of STI vaccines to prevent transmission is a crucial research priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.